Triple therapy with sucralfate is not effective in eradicating Helicobacter pylori and does not reduce duodenal ulcer relapse rates.
OBJECTIVE
The most used therapeutic schedule to eradicate Helicobacter pylori is the "triple therapy," which is based on the simultaneous use of a bismuth salt and two antibiotics. Sucralfate, a basic aluminum salt of sucrose sulfate, is supposed to have an antibacterial activity and is said to reduce the bacterial density of H. pylori. This randomized, prospective clinical trial compares the efficacy of an alternative oral triple therapy consisting of sucralfate, tinidazol, and tetracycline with a conventional therapy using ranitidine, with respect to H. pylori eradication and duodenal ulcer healing and recurrence in a 12-month follow-up.


METHODS
Forty-three patients with active duodenal ulcers diagnosed at endoscopy were enrolled to receive either 1 g of sucralfate four times daily for 30 days, 500 mg of tetracycline four times daily, and 500 mg of tinidazol three times daily, for 10 days (group A; n = 23) or 150 mg of ranitidine twice daily for 30 days (group B; n = 20). The groups were age- and sex-matched and balanced for tobacco use and H. pylori status. Compliance assessed by post-treatment interviews was considered high (all patients declared that they had ingested at least 80% of the drugs).


RESULTS
Both therapies were efficient in healing ulcers (group A, 95%; group B, 90%), the relapse rates were high in both groups (group A, 77%; group B, 89%), and the alternative triple therapy eradicated H. pylori in only 4% of the patients.


CONCLUSIONS
Alternative oral triple therapy presented no significant advantage over ranitidine treatment of active ulcer disease.
Pedrazzoli
J
J
Department of Internal Medicine, São Francisco University Medical School, Paulista-S.P., Brazil.
Magalhães
A F
AF
Ferraz
J G
JG
Trevisan
M
M
De Nucci
G
G
D000328:Adult; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000453:epidemiology; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D015995:Prevalence; D011899:Ranitidine / Q000627:therapeutic use; D012008:Recurrence; D013392:Sucralfate / Q000627:therapeutic use*; D013752:Tetracycline / Q000627:therapeutic use; D013997:Time Factors; D014011:Tinidazole / Q000627:therapeutic use
D014011:Tinidazole; D013392:Sucralfate; D011899:Ranitidine; D013752:Tetracycline